Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)

References

• Dalbeth N, Gosling AL, Gaffo A, et al. Gout. Lancet. 2021;397(10287):1843–1855.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Podestà MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 2020;98(5):1149–1159.
   PubMed Web of Science ®Google Scholar
• Zhao J, Guo S, Schrodi SJ, et al. Trends in the contribution of genetic susceptibility loci to hyperuricemia and gout and associated novel mechanisms. Front Cell Dev Biol. 2022;10:937855.
   PubMed Web of Science ®Google Scholar
• Keenan RT. The biology of urate. Semin Arthritis Rheum. 2020;50(3s):2–10.
   Google Scholar
• Li Z, Hoshino Y, Tran L, et al. Phylogenetic articulation of uric acid evolution in mammals and how it informs a therapeutic uricase. Mol Biol Evol. 2022;39(1):312.
   Web of Science ®Google Scholar
• Whitehouse MW, Kippen I, Klinenberg JR, et al. Increasing excretion of urate with displacing agents in man. Ann N Y Acad Sci. 1973;226:309–318.
   PubMed Web of Science ®Google Scholar
• Xu L, Shi Y, Zhuang S, et al. Recent advances on uric acid transporters. Oncotarget. 2017;8(59):100852–100862.
   PubMedGoogle Scholar
• Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;58:663–687.
   PubMed Web of Science ®Google Scholar
• Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet. 2009;18(R2):177–184.
   PubMedGoogle Scholar
• Singh JV, Bedi PMS, Singh H, et al. Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020). Expert Opin Ther Pat. 2020;30(10):769–780.
   PubMed Web of Science ®Google Scholar
• Badve S, Pascoe E, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513.
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–1757.
   PubMed Web of Science ®Google Scholar
• Song D, Zhao X, Wang F, et al. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications. Eur J Pharmacol. 2021;907:174291.
   PubMed Web of Science ®Google Scholar
• Kang EH, Park EH, Shin A, et al. Cardiovascular risk associated with allopurinol vs. Eur Heart J. 2021;42(44):4578–4588.
   PubMed Web of Science ®Google Scholar
• On PC. Lesinurad (Zurampic) for Gout. Am Fam Physician. 2018;97(6):374–375.
   PubMed Web of Science ®Google Scholar
• Dong Y, Zhao T, Ai W, et al. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). Expert Opin Ther Pat. 2019;29(11):871–879.
   PubMed Web of Science ®Google Scholar
• Azevedo VF, Kos IA, Vargas-Santos AB, et al. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019;59(1):37.
   PubMedGoogle Scholar
• Felser A, Lindinger PW, Schnell D, et al. Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. Toxicology. 2014;324:136–146.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Takahashi T, Taniguchi T, et al. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021;22(11):1397–1406.
   PubMed Web of Science ®Google Scholar
• Uda J, Kobashi S, Miyata S, et al. Discovery of dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity. ACS Med Chem Lett. 2020;11(10):2017–2023.
   PubMed Web of Science ®Google Scholar
• Ahn SO, Ohtomo S, Kiyokawa J, et al. Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther. 2016;357(1):157–166.
   PubMed Web of Science ®Google Scholar
• Wu YC, Chen X, Huang SQ, et al. Heterocyclic compounds, preparation method and use thereof in medicine. WO2019141259A1. 2019.
   Google Scholar
• Zhou ZW, Liu B, Zhou CL, et al. Heterocyclic derivatives and use thereof. WO2020253659A1. 2020.
   Google Scholar
• Shi D, Zhou H, Zhu J, et al. URAT1 inhibitor and application thereof. CN114213331A. 2022.
   Google Scholar
• Wu Tom Yao-Hsiang, Jin Qihui. Inhibitors of URAT1 and pharmaceutical uses thereof. WO2022169974A1. 2022.
   Google Scholar
• Prakash G, Paul N, Oliver G, et al. C-H deuteration of organic compounds and potential drug candidates. Chem Soc Rev. 2022;51(8):3123–3163.
   PubMed Web of Science ®Google Scholar
• Yan S, Yeh L, Yan R. Methods for treating of preventing gout or hyperuricemia. WO2020118114A1. 2020.
   Google Scholar
• Fu X, Gao J, Zhong G, et al. Compound for preventing, treating or alleviating hyperuricemia or gout and application thereof. CN112430221A. 2021.
   Google Scholar
• Hoy SM. Lesinurad: first global approval. Drugs. 2016;76(4):509–516.
   PubMed Web of Science ®Google Scholar
• Sanchez-Niño MD, Zheng-Lin B, Valiño-Rivas L, et al. Lesinurad: what the nephrologist should know. Clin Kidney J. 2017;10(5):679–687.
   PubMed Web of Science ®Google Scholar
• Tan PK, Liu S, Gunic E, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017;7(1):665.
   PubMed Web of Science ®Google Scholar
• Lin Y, Chen X, Ding H, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021;60(11):5089–5097.
   PubMed Web of Science ®Google Scholar
• Zhao T, Meng Q, Sun Z, et al. Novel human urate transporter 1 inhibitors as hypouricemic drug candidates with favorable druggability. J Med Chem. 2020;63(19):10829–10854.
   PubMed Web of Science ®Google Scholar
• Peng J, Hu Q, Gu C, et al. Discovery of potent and orally bioavailable inhibitors of human uric acid transporter 1 (hURAT1) and binding mode prediction using homology model. Bioorg Med Chem Lett. 2016;26(2):277–282.
   PubMed Web of Science ®Google Scholar
• Liu X, Ai W, Zhan P, et al. Thienopyrimidinone mercaptoacetic acid derivative as well as preparation method and application thereof. CN111763218A. 2020.
   Google Scholar
• Liu X, Ai W, Zhan P, et al. Thienopyrimidone acyl sulfonamide derivative as well as preparation method and application thereof. CN113336769B. 2021.
   Google Scholar
• Liu Y, Li J, Ding J, et al. Thiophene derivatives used as inhibitor of URAT1. CN109608432A. 2019.
   Google Scholar
• Wang J, Zhang Y, Zhu W, et al. Thiophene, manufacturing method thereof, and pharmaceutical application of same. CN109790155B. 2022.
   Google Scholar
• Wang J, Zhang Y, Zhu W, et al. Crystal form of URAT1 inhibitor, and preparation method therefor. WO2019101058A1. 2019.
   Google Scholar
• Wang J, Zhang Y, Zhu W, et al. Uric acid discharge promoting agent as well as synthesis method and medical application thereof. WO2021083182A1. 2021.
   Google Scholar
• Shiramoto M, Liu S, Shen Z, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford). 2018;57(9):1602–1610.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wyatt D, Stazzone K, et al. OP0205 phase I study of D-0120, a novel URAT1 inhibitor in clinical development for hyperuricaemia and gout. Ann Rheum Dis. 2020;79(Suppl 1):127–128.
   Google Scholar
• Xu ZS, Zhang N, Sun QR, et al. Condensed ring derivatives, and preparation methods, intermediates, pharmaceutical composition and use thereof. WO2016150255A1. 2016.
   Google Scholar
• Jin H, Wu F, Yu Z, et al. URAT1 inhibitor as well as preparation method and application thereof. CN114315705A. 2022.
   Google Scholar
• Pang J, Chen J, Tian Y, et al. Pyridine 3-amine derivative as well as preparation method and application thereof. CN113979931A. 2022.
   Google Scholar
• Chen J, Huang L, Xie F. Pyridine thioglycolic acid compound and preparation method therefor, pharmaceutical derivative or formulation thereof, and application thereof. WO2022121222A1. 2022.
   Google Scholar
• Tang H, Cui B, Chen Y, et al. Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study. Ther Adv Musculoskelet Dis. 2022;14:1759720x211067304.
   Web of Science ®Google Scholar
• Huang H, Gang L, Meng B, et al. Quinoline formamide compound as well as preparation method and application thereof. CN111943957A. 2020.
   Google Scholar
• Zhang P, Xu S, Zhu Z, et al. Multi-target design strategies for the improved treatment of Alzheimer’s disease. Eur J Med Chem. 2019;176:228–247.
   PubMed Web of Science ®Google Scholar
• Artasensi A, Pedretti A, Vistoli G, et al. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;25(8):1987.
   PubMed Web of Science ®Google Scholar
• Fernandez-Prado R, Ortiz A. Verinurad/Febuxostat and Nephrotoxicity. Am J Kidney Dis. 2021;78(3):468.
   PubMed Web of Science ®Google Scholar
• Abramowicz M, Zuccotti G, Pflomm JM. Lesinurad/Allopurinol (Duzallo) for gout-associated hyperuricemia. Jama. 2018;319(2):188–189.
   PubMed Web of Science ®Google Scholar
• Dua P, Gurrell R, Kirby S, et al. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clin Rheumatol. 2016;35(8):2045–2051.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Merriman TR, Singh JA. Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs. 2018;23(3):201–209.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou H, Zhu X, et al. Preparation and application of oxygen substituted phenylimidazole XOR/URAT1 dual inhibitors. CN110204494A. 2019.
   Google Scholar
• Li J, Zhu X, Yang C, et al. N-Substituted benzothiazolinone XOR/URAT1 dual inhibitors and their preparation methods and applications. CN113087683A. 2021.
   Google Scholar
• Piwinski J, Buckle R, Larivée A, et al. Compounds and Their Use for Reducing Uric Acid Levels. US20220024900A1. 2022.
   Google Scholar
• Wang S, Gao J, Meng W, et al. Indole derivative as well as preparation method and application thereof. CN113004188A. 2021.
   Google Scholar
• Li J, Yang C, Zhu XY, et al. Tricyclic XOR/URAT1 dual inhibitor containing 2-hydroxybenzoic acid as well as preparation method and application of tricyclic XOR/URAT1 dual inhibitor. CN114805192.2022.
   Google Scholar
• Zhang Y, Wu WT, Zhu WY, et al. Thiophene derivatives as xanthine oxidase inhibitors and application thereof. WO2021083319A1. 2021.
   Google Scholar
• Hu Q, Zhou M, Zhu H, et al. (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. Biomed Pharmacother. 2017;86:88–94.
   PubMed Web of Science ®Google Scholar
• Yong T, Liang D, Xiao C, et al. Hypouricemic effect of 2,4-dihydroxybenzoic acid methyl ester in hyperuricemic mice through inhibiting XOD and down-regulating URAT1. Biomed Pharmacother. 2022;153:113303.
   PubMed Web of Science ®Google Scholar
• Qin Z, Wang S, Lin Y, et al. Antihyperuricemic effect of mangiferin aglycon derivative J99745 by inhibiting xanthine oxidase activity and urate transporter 1 expression in mice. Acta Pharm Sin B. 2018;8(2):306–315.
   PubMed Web of Science ®Google Scholar
• Ao GZ, Zhou MZ, Li YY, et al. Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents. Bioorg Med Chem. 2017;25(1):166–174.
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhang J, Tao Y, et al. Discovery of novel bicyclic imidazolopyridine-containing human urate transporter 1 inhibitors as hypouricemic drug candidates with improved efficacy and favorable druggability. J Med Chem. 2022;65(5):4218–4237.
   PubMed Web of Science ®Google Scholar
• Tian W, Chen C, Lei X, et al. CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res. 2018;46(W1):363–367.
   PubMed Web of Science ®Google Scholar
• Lu J, Dalbeth N, Yin H, et al. Mouse models for human hyperuricaemia: a critical review. Nat Rev Rheumatol. 2019;15(7):413–426.
   PubMed Web of Science ®Google Scholar
• Zhou H, Zhong G, Bai J, et al. Development of a fluorescence-based assay for screening of urate transporter 1 inhibitors using 6-carboxyfluorescein. Anal Biochem. 2021;626:114246.
   PubMed Web of Science ®Google Scholar
• Hou C, Hu Y, Jiang H, et al. Establishment of a 3D hyperuricemia model based on cultured human liver organoids. Free Radic Biol Med. 2022;178:7–17.
   PubMed Web of Science ®Google Scholar